{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000772","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.188621+00:00","generated_at":"2026-06-07T02:09:54.512072+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ardelyx reports preliminary Q4 2023 IBSRELA net sales of ~$28M, full year ~$80M, and XPHOZAH ~$2.5M","bullets":["IBSRELA US net sales: Q4 ~$28M, FY2023 ~$80M (unaudited).","XPHOZAH US net sales: Q4 ~$2.5M (unaudited).","Cash and investments ~$184M as of Dec 31, 2023 (unaudited)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000772","json":"https://secwatch.observer/filing/0001628280-24-000772.json","markdown":"https://secwatch.observer/filing/0001628280-24-000772.md","text":"https://secwatch.observer/filing/0001628280-24-000772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/0001628280-24-000772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/ardx-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:09:54.512072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c11d0abe1316ac41a55fe253c63c1908b3e2cd4b","claim":"ARDELYX, INC. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28 million.","evidence_excerpt":"On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/0001628280-24-000772-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"approximately $28 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"c61d3e8b25f527ae7ede7bae83b572ba0fc46344","claim":"ARDELYX, INC. reported the full year ended December 31, 2023 results: revenue approximately $80 million.","evidence_excerpt":"On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023, and approximately $80 million for the full year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024000772/0001628280-24-000772-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"approximately $80 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}